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A B S T R A C T
Background and purpose: Proton therapy (PT) of extra-cranial tumour sites is challenged by density changes caused by inter-fractional organ motion. In this study we
investigate on-line dose-guided PT (DGPT) to account inter-fractional target motion, exemplified by internal motion in the pelvis.
Materials and methods: On-line DGPT involved re-calculating dose distributions with the isocenter shifted up to 15 mm from the position corresponding to con-
ventional soft-tissue based image-guided PT (IGPT). The method was applied to patient models with simulated prostate/seminal vesicle target motion of ± 3, ± 5
and ± 10 mm along the three cardinal axes. Treatment plans were created using either two lateral (gantry angles of 90°/270°) or two lateral oblique fields (gantry
angles of 35°/325°). Target coverage and normal tissue doses from DGPT were compared to both soft-tissue and bony anatomy based IGPT.
Results: DGPT improved the dose distributions relative to soft-tissue based IGPT for 39 of 90 simulation scenarios using lateral fields and for 50 of 90 scenarios using
lateral oblique fields. The greatest benefits of DGPT were seen for large motion, e.g. a median target coverage improvement of 13% was found for 10 mm anterior
motion with lateral fields. DGPT also improved the dose distribution in comparison to bony anatomy IGPT in all cases. The best strategy was often to move the fields
back towards the original target position prior to the simulated target motion.
Conclusion: DGPT has the potential to better account for large inter-fractional organ motion in the pelvis than IGPT.
1. Introduction
Proton therapy (PT) is currently being investigated for a number of
tumour sites due to the favourable depth dose characteristics of pro-
tons. However, the sharp distal dose fall-off in proton beams makes this
treatment modality sensitive towards density changes. A study of the
robustness of intensity modulated PT (IMPT) plans showed that small
inter-fractional translational set-up errors for cranial tumours degraded
the dose distribution severely, with the extent depending on beam di-
rections [1]. Treatment of extra-cranial tumour sites is an even greater
challenge since larger anatomical changes may occur during the course
of treatment, originating from weight loss, tumour shrinkage and/or
inter-fractional motion and set-up/posture changes [2–8]. The dose
distribution may therefore deteriorate, with inferior target coverage
and increased doses to the normal tissues [9]. It has been shown that
selecting beam angles from variations inside the beam path in tissue
density or water equivalent path length may reduce the impact of
motion for IMPT [10–14].
The main approach to account for inter-fractional variation in
radiotherapy (RT) is on-line image-guidance, based on imaging of fi-
ducial markers, bony anatomy and/or soft tissue, with the patient
aligned in treatment position. However, we and others have shown that
image-guided PT (IGPT) have difficulties in avoiding motion-induced
target dose degradations [5,15–17]. Vargas et al. investigated the im-
pact of prostate motion using PT and found dose coverage to be ade-
quate for small motion (less than 5 mm), while beam realignment im-
proved coverage for larger displacements [18].
The concept of dose-guided RT (DGRT) was proposed as an alter-
native to image-guidance based on reference anatomy by Cheung et al.
[19]. Haehnle et al. later explored DGRT using pareto fronts for selec-
tion of the most beneficial isocenter positioning in treatment of prostate
as well as head and neck cancer [20]. Cheung et al. [21] further applied
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dose-guidance to PT (DGPT) exploring pre-calculated isocenter shifts to
account for anatomical changes in lung cancer patients and found that
dose-based isocenter adjustments of passive scattering proton fields was
able to improve the dose distributions compared to IGPT. Building upon
this work we here propose the concept of on-line DGPT, which involves
the use of on-line dose re-calculations of possible isocenter shifts to find
the optimal re-positioning of the patient without the use of pre-calcu-
lated isocenter shifts.
The aim of the study was therefore to investigate the potential of on-
line DGPT to restore target coverage and minimise the normal tissue
dose compared to IGPT, exemplified by inter-fractional target motion in
the pelvis. We also wanted to demonstrate whether beam angle selec-
tion of robust angles reduced the possible benefit of on-line DGPT, and
we therefore explored the method for two different PT beam config-
urations.
2. Materials and methods
2.1. Dose-guidance
On-line DGPT (Suppl. Fig. 1) was explored by calculating multiple
dose distributions with the isocenter shifted an additional ± 1, ± 2,
± 3, ± 5, ± 10 and ± 15 mm along the three cardinal axes away from
the field position used for the soft-tissue based IGPT re-calculation,
giving a total of 36 DGPT dose distributions for each simulated inter-
fractional motion (Suppl. Fig. 2). We also counted the position corre-
sponding to soft-tissue based IGPT as a possible DGPT alternative. We
focused on the ability of DGPT to counteract the effects of inter-frac-
tional motion without performing an exhaustive search across all pos-
sible shifts, and without any consideration of dose calculation times.
Conventional soft-tissue based IGPT was investigated by shifting the
plan isocenter the same amount as the simulated motion followed by
plan re-calculation. A DGPT dose distribution was found superior if it
resulted in a better target coverage compared to soft-tissue based IGPT,
for all three targets and a lower dose to the normal tissue (criteria given
in ‘Data analysis’). The same constraints were used when investigating
bony anatomy based image-guidance. Results from bony anatomy
based IGPT was also compared to DGPT using the same constraints, if
an improved DGPT plan had been found.
2.2. Patient models and motion simulations
Five patient models were created using a planning CT (pCT) and
four repeat CTs (rCTs) of a patient with locally advanced prostate
cancer. Air, soft tissue and bones were delineated in all five scans and
the Hounsfield Units (HUs) were afterwards overwritten to air, water
and the average of bone for the specific patient to enable motion si-
mulations and to isolate the effects of inter-fractional target and patient
motion. The rCTs were included in the study to investigate the effects of
surface and posture changes.
The prostate planning target volume (PTV) was created in the pCT
scan by expanding the prostate clinical target volume (CTV-p) 7 mm in
all directions, except in the superior-inferior direction, where 9 mm was
used. The CTVs of the lymph nodes (CTV-ln) and seminal vesicles (CTV-
sv) were expanded by 5 mm and 8 mm in the superior-inferior direction
to create the corresponding PTVs. These margins were identical to the
margins used clinically when treating prostate cancer patients with
photon-based RT at Aarhus University Hospital. The normal tissue in
each CT was defined as the complete patient volume (i.e. the body
contour) with the CTVs subtracted.
Inter-fractional motion was simulated by moving the prostate and
SV PTVs ± 3, ± 5 and ± 10 mm together along the three cardinal axes
using MIM (MIM Software Inc., Cleveland, Ohio, US) and MATLAB
(MATLAB and Statistics Toolbox Release 2017b, The MathWorks, Inc.,
Natick, Massachusetts, US), while keeping the lymph node (LN) PTV
stationary in the patient models, resulting in 90 scenarios of composite
prostate and SV motion (Suppl. Fig. 2).
2.3. Treatment planning
Two IMPT plans using multi-field optimisation were created
(Eclipse treatment planning system (TPS), Varian Medical Systems, Palo
Alto, CA, USA) on the pCT, with one using two lateral opposed beams
(gantry angles 90°/270°) and the other using two lateral oblique beams
(gantry angles 35°/325°) identified in a previous inter-fractional ro-
bustness study [14] (Suppl. Fig. 3). The prescribed doses were 78 Gy in
39 fractions for the prostate PTV and 56 Gy in the same number of
fractions for the combined LN and SV PTV (planning constraints ac-
cording to in-house photon-based clinical protocols; Suppl. Table A). A
soft-tissue and a bony anatomy based rigid registration were performed
between the pCT and rCTs before transferring the IMPT plans to the
rCTs. The soft-tissue registration was based on the isocenter of the
prostate using MIM. Bony anatomy IGPT was explored in the rCTs (i.e.
the fields were stationary with respect to bony anatomy).
To relate the effect of DGPT to dose-guidance in conventional
photon-based RT, we also created a volumetric modulated arc therapy
(VMAT) plan on the pCT. The VMAT plan used two 15MV arcs, one arc
from 181° to 179° in a clockwise rotation and the other arc from 179° to
181° counter clockwise. Dose-guidance with VMAT was investigated
only for 10 mm anterior motion.
2.4. Data analysis
The resulting DGPT and IGPT dose distributions were evaluated on
the CTV coverage using the volume receiving 98% of the prescribed
dose (V98%) for all targets, while the normal tissue was evaluated
based on the maximum dose to 1 cc (D1cc).
We particularly investigated if the dose distributions with DGPT had
better V98% coverage of all three CTV targets and a lower D1cc to the
normal tissue compared to the soft-tissue based IGPT dose distribution.
If this was fulfilled by more than one DGPT dose distribution, the dis-
tribution with the highest prostate CTV coverage was chosen.
3. Results
Improvements in dose distribution using DGPT varied between the
two field configurations and the extent of motion simulated. For each of
the 30 simulations with 3 mm, 5 mm and 10 mm motion using lateral
fields, DGPT gave a better dose distribution compared to soft-tissue
based IGPT 7, 11 and 21 times. For 6, 11 and 19 times it was best to
move the fields back towards the isocenter of the CTV-p at its original
placement prior to simulated target motion (the uncorrected position
prior to image-guidance), respectively. For the 24 simulations using
bony anatomy based IGPT in the rCTs, DGPT improved the dose dis-
tribution 6, 8 and 17 times. For the lateral oblique fields it was best to
move the fields back for 8, 9 and 13 times out of 17, 17 and 16 times for
3, 5 and 10 mm, where DGPT gave a better dose distribution than soft-
tissue based IGPT. For the 24 simulations using bony anatomy based
IGPT, DGPT was superior 13, 11 and 11 times.
DGPT improved the dose distribution from lateral fields beyond
soft-tissue based IGPT for a total of 39 out of 90 shifts; 31 of these shifts
occurred in the rCTs, with DGPT being superior to both soft-tissue and
bony anatomy based IGPT for all these shifts. The fields were moved
towards the uncorrected position in 92% of the shifts where DGPT were
superior to soft-tissue based IGPT. The greatest improvement of DGPT
compared to soft-tissue based IGPT occurred for 5 and 10 mm inter-
fractional motion in the anterior direction when lateral fields were
applied (Figs. 1 and 2). Here target coverage increased when using
DGPT instead of soft-tissue based IGPT with a median of 13, 9 and 3
percentage points for the CTV-p, CTV-sv and CTV-ln. At the same time
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the normal tissue doses were reduced with DGPT. Similarly, for 5 and
10 mm motion in the inferior direction, DGPT resulted in a median
increase compared to soft-tissue based IGPT of 3 percentage points for
the CTV-sv (Suppl. Mat. A). For 10 mm inferior motion in the pCT, a
reduction in D1cc for the normal tissue of 11 Gy was found. Applying
DGPT to counteract inter-fractional motion in the posterior, superior,
left and right directions had small or no improvements beyond IGPT
(Suppl. Mat. A).
DGPT gave in all cases better dose distributions than bony anatomy
based image-guidance. However looking at the three targets separately
the doses were better with bony anatomy image-guidance for anterior
shifts using lateral fields for 11, 8 and 2 out of 12 rCTs for the CTV-p,
CTV-sv and CTV-ln, respectively. The median target dose improvement
across all 12 rCTs for each target was 2, 6 and −0.4 percentage points.
For posterior motion using lateral fields a large dose degradation were
seen in almost all rCTs using bony anatomy based IGPT with a median
decrease of 12 percentage points and 24 percentage points for CTV-p
and CTV-sv (Fig. 2).
For the lateral oblique fields, DGPT gave a better dose distribution
compared to soft-tissue based IGPT in 50 out of 90 times, and in 60% of
the shifts where DGPT were superior to soft-tissue based IGPT it was
better to move the fields back towards the uncorrected position. A total
of 35 out of the 50 shifts occurred in the rCTs and for all 35 shifts DGPT
gave a better dose distribution compared to both soft-tissue based IGPT
and bony anatomy based IGPT. However, once where DGPT could not
improve the dose distribution compared to soft-tissue based IGPT, bony
anatomy based IGPT were found superior to soft-tissue based IGPT,
which occurred for 10 mm right shift in rCT no. 3. The greatest target
coverage improvements from soft-tissue based IGPT to DGPT occurred
for 3 mm inferior motion, where a target increase of 10 percentage
points were seen for the CTV-sv in one of the rCTs (Suppl. Mat. B). A
large reduction in normal tissue doses were seen for both 3, 5 and
10 mm motion in the pCT for inferior motion (median decrease of 26 Gy
with DGPT). A median increase of 10, 8 and 6 percentage points for the
CTV-p, CTV-sv and CTV-ln occurred in two of the five CTs for posterior
motion (Fig. 3). For motion to the right, an increase of 9 and 17 per-
centage points were seen for the CTV-p in the pCT for 5 and 10 mm and
in the latter, an 8 percentage points increase occurred for the CTV-ln
(Suppl. Mat. B). Motion in the left, superior and anterior directions
showed small or no improvements using DGPT (Suppl. Mat. B).
A DGPT plan was found superior to soft-tissue based IGPT 9 out of
the 18 shifts that was made in the pCT, compared to 31 times out of 72
shifts in the rCTs. For the same simulated motion using lateral fields,
the preferred DGPT shift in the pCT and rCTs were identical only 5
times out of the 9 and 31 times DGPT was found superior. For the
lateral oblique fields a DGPT plan was found superior 15 and 35 times
in the pCT and rCTs, respectively. Similar to the lateral fields the pre-
ferred shifts for the same simulated motion in the pCT and rCTs were
identical 5 times.
When DGPT gave a superior dose distribution compared to soft-
tissue based IGPT, each target often had a V98% coverage below the
value from the original (Table 1). Only in one distribution had all three
targets a V98% value similar or higher than in the original pCT plan,
which occurred for 5 mm anterior shift using lateral fields. It was most
often the CTV-sv that had a similar coverage in both the pCT and rCTs
for both field configurations and motion simulations.
In the investigation of dose-guidance for VMAT using 10 mm ante-
rior motion, minor improvements from soft-tissue based and bony
anatomy based IGPT to DGPT was found. The median increase from
soft-tissue based IGPT to DGPT was 12, 2 and 4 percentage points for
CTV-p, CTV-sv and CTV-ln using two lateral proton fields and 0.5, 0 and
2 percentage points for two lateral oblique proton fields, while it was 1,
2 and 4 percentage points using VMAT. For the normal tissue a median
decrease of 6 Gy, 3 Gy and 1 Gy were found for the lateral proton fields,
lateral oblique proton fields and VMAT, respectively (Table 2). The
targets median increases using bony anatomy based IGPT to DGPT were
−1.5, 0.5 and 0 percentage points for lateral fields and 1, 4.5 and −5.5
percentage points for lateral oblique fields. A median decrease of 0.5
and −9 percentage points occurred for the normal tissue for the lateral
proton fields and lateral oblique proton fields (Table 2).
4. Discussion
In this study we have investigated the use of on-line dose-guided
isocenter shifts to account for inter-fractional motion during PT – in
comparison with conventional image-guidance – with the aim of re-
storing target coverage and reducing normal tissue doses. We found
that DGPT improved the dose distributions, but that the degree of im-
provement depended on the extent of motion simulated and the field
configuration studied. In general, we found that shifting the fields back
towards the uncorrected position (pre image-guidance) resulted in an
improved dose distribution. This implies that soft-tissue based image-
guidance might ‘over-correct’ the shifts derived only from the target
image and that ideal shifts for PT will depend on both the target po-
sition and the patient’s anatomy (in particular the bony anatomy).
However DGPT was better than bony anatomy based image-guidance in
all cases with the constraints we had chosen. In one case where dose-
guidance did not improve the dose distribution beyond soft-tissue based
IGPT, bony anatomy based image-guidance gave a better target cov-
erage.
Target coverage is a main concern in PT, however we have shown
that on-line DGPT can improve target dose, although the increase may
not always be sufficient to obtain clinically acceptable dose coverage
according to planning constraints; e.g. for posterior motion using lateral
fields, often no or only small target improvements were found, due to
the dose gradient towards the rectum. The same was seen for left and
right motion using lateral fields, since the targets were moved along the
beam path. The applied PTV margins help secure the target coverage for
small inter-fractional motion and dose-guidance may therefore not
improve the dose distribution in these cases. When DGPT improved the
dose distribution it was often best to move the fields back towards the
uncorrected position minimising the density changes caused by bony
anatomy. Vargas et al. also found realignment of proton beams to give a
modest improvement in CTV coverage for prostate motion smaller than
Fig. 1. Dose distribution for 10 mm anterior motion for a) bony based IGPT, i.e., the plan was moved from the pCT to the rCT based on bony anatomy, b) soft-tissue
based IGPT, i.e. the fields are at the isocenter of the moved target after a soft-tissue registration and c) DGPT, where the preferred dose distribution have been chosen,
which in this case is when the fields are moved 5 mm posterior towards the uncorrected position prior to IGPT.
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the PTV margin [22]. When the fields were moved back to the un-
corrected position, the target dose improved due to the applied PTV
margin. It also improved normal tissue sparing, since the high dose
distribution is aligned better to the targets, which allows the dose fall-
off to be appropriately aligned to the nearby organs.
The choice of beam angles in PT is important not only for normal
tissue sparing but also for increasing plan robustness (i.e. securing
target coverage), which combined with DGPT may reduce the need for
re-planning. In our study large dose deterioration occurred for 10 mm
posterior motion using lateral oblique fields. These could not be fully
resolved using DGPT, although the dose distribution improved sub-
stantially. The large dose deterioration was due to the dose gradient
towards the rectum. However, in other cases DGPT improved the target
coverage sufficiently, which e.g. was seen in some of the CTs for si-
mulated motion to the right. This opens up for the possibility to treat
patients using lateral oblique proton fields, which may be beneficial for
patients with e.g. hip prosthesis or who have been irradiated through
their hip previously [23]. Lateral oblique fields were also explored in a
study by Moteabbed et al. with focus on the impact of setup and ana-
tomical variations in prostate cancer, showing that the field
Fig. 2. V98%/D1cc for the soft-tissue (black circles) and bony anatomy (black crosses) based IGPT plans and the best DGPT (open circles) dose distribution for the
CTVs and normal tissue using two lateral fields. Motion of 3, 5 and 10 mm in the anterior and posterior direction in all CT-scans were simulated (pCT and four rCTs).
The vertical line depicts the V98% value from the original pCT plan. Normal tissue was defined as everything except CTV targets and bones.
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configuration was sensitive towards inter-fractional motion, causing
target underdosage [24]. However in another study of pelvic LN irra-
diation with protons, lateral oblique fields were found robust towards
density changes [14].
The concept of on-line dose-guidance builds on the work by Cheung
et al., who suggested off-line dose-guidance for (passive scattering) PT.
Their workflow was based on exhaustive dose pre-calculations [21]. In
our study we have used multi-field optimised IMPT which improves the
dose conformity, yet may make the plans less robust towards inter-
fractional motion. On-line dose-guidance has considerable implications
for the implementation into the clinical workflow in regards to software
integration such as automatic contouring and scatter-correction of
CBCTs. Several groups are working on the latter making it possible to
calculate more accurate proton dose distributions [25–27]. Manual
contouring is time consuming and organ motion can occur in the time it
takes to contour the relevant structures, hence fast contouring is ne-
cessary [26–29]. Regarding on-line dose calculations, the TPS (Eclipse)
used in this study can be used to search for the optimal field position
along the three cardinal axes. It took approximately three minutes to
calculate 36 DGPT dose distributions; however with a modern processor
a 1.5x speed-up could possibly be achieved. Pareto sliders are also a
possibility, which have been implemented and investigated by Haehnle
et al. [20], who concluded that an optimised dose-guidance workflow
can be performed in minutes.
Different from previous dose-guidance studies, we looked at si-
multaneous coverage of three targets. We found it difficult to get a
sufficient coverage of all targets at once, similar to Thörnqvist et al.,
Fig. 3. V98%/D1cc for the soft-tissue (black circles) and bony anatomy (black crosses) based IGPT plans and the best DGPT (open circles) dose distribution for the
CTVs and normal tissue using two lateral oblique fields. Motion of 3, 5 and 10 mm in the posterior direction in all CT-scans were simulated (pCT and four rCTs). The
vertical line depicts the V98% value from the original pCT plan. Normal tissue was defined as everything except CTV targets and bones.
Table 1
The percentage of motion simulations in all CT-scans, where the three CTVs had
a target coverage higher than in the original pCT for ± 3 mm, ± 5 mm and ±
10 mm along the three cardinal axes. The columns shows the percentage for a
target coverage higher than in the original pCT using DGPT compared to soft-
tissue based IGPT for each target.
CTV-p [%] CTV-sv [%] CTV-ln [%]
90°/270°
± 3 mm 12.5 62.5 25
± 5 mm 27 45.5 45.5
± 10 mm 0 9.5 9.5
35°/325°
± 3 mm 6 29 0
± 5 mm 18 35 6
± 10 mm 6 31 0
Table 2
V98% for the three targets and D1cc for the normal tissue (all tissue with the
CTVs subtracted) for a 10 mm anterior simulated motion. The results are shown
for the soft-tissue based and bony anatomy based IGPT plans and best DGPT
dose distribution for both configurations in all scans and for photons in the pCT.























pCT x | 86 | 99 x | 74 | 83 x | 93 | 96 x | 86 | 80
rCT1 96 | 80 | 92 70 | 71 | 73 94 | 83 | 93 88 | 88 | 85
rCT2 99 | 86 | 99 96 | 67 | 90 94 | 91 | 95 82 | 87 | 81
rCT3 100 | 88 | 99 78 | 70 | 77 95 | 93 | 96 81 | 89 | 84
rCT4 99 | 86 | 97 98 | 74 | 100 97 | 90 | 96 84 | 97 | 84
35°/325°
pCT x | 98 | 98 x | 100 | 100 x | 90 | 91 x | 97 | 95
rCT1 95 | 97 | 97 81 | 92 | 92 92 | 79 | 79 99 | 107 | 107
rCT2 98 | 99 | 100 96 | 100 | 100 91 | 85 | 88 88 | 102 | 98
rCT3 99 | 98 | 98 94 | 99 | 99 94 | 90 | 90 81 | 91 | 91
rCT4 96 | 96 | 96 99 | 100 | 100 86 | 79 | 79 109 | 110 |
110
VMAT
pCT x | 97 | 98 x | 95 | 97 x | 87 | 91 x | 83 | 82
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who also found it difficult to cover all targets no matter the choice of
alignment method or the use of wider margins [5]. In the case where
target coverage cannot be restored a full-fledged re-planning or the use
of a back-up plan might be needed. The constraints we used to de-
termine when a plan is acceptable are very strict. Bony anatomy based
IGPT could be preferred compared to dose-guidance for certain simu-
lated shifts if the constraints were more flexible, e.g. for anterior mo-
tion, where an improved dose to the prostate and seminal vesicles was
observed, with a slightly lower dose to the lymph nodes. In addition,
our normal tissue dose constraints focusing on maximum dose may also
not be suitable for all OARs in the pelvis.
In this study we have used simplified patient models and our results
do therefore not take the full complexity of organ motion and tissue
heterogeneity into account. Further investigations on volumetric (CT)
images using a larger patient cohort would therefore be warranted.
However, even using simplified patient anatomies, we have shown that
posture/surface changes and inter-fractional motion may have an im-
pact on the dose distributions.
Inter-fractional motion may also be accounted for by using robust
optimisation, where uncertainties in range and patient set-up are taken
into account during plan optimization and no PTV margins are used
[30,31]. A study found robust optimisation to provide robust target
coverage for different tumour sites [32]. However robust optimised
plans are less conformal than multi-field optimised IMPT plans [33] and
most robust optimisation implementations do not take anatomical
changes per se (as seen in online volumetric imaging) into considera-
tion. However, DGPT and robust optimisation have the potential both
individually and combined to reduce the need for a full-fledged adap-
tive re-planning during treatment, which has strong implications for the
planning and treatment workflow (including pre-treatment plan ver-
ifications).
In conclusion, this study showed that DGPT can improve the target
and normal tissue doses in around half of the scenarios for both field
configurations investigated. However, it was difficult to restore target
coverage in all targets at once. In addition, we found that it was mainly
for large simulated motion that dose deterioration occurred and it was
often best to shift the fields back towards the uncorrected position.
Further studies are needed to show if the potential of DGPT found in
this study transfers across to an even more clinically realistic scenario.
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